Literature DB >> 29569494

N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure.

Chiara Arzilli1, Alberto Aimo2, Giuseppe Vergaro1,2, Andrea Ripoli1, Michele Senni3, Michele Emdin1,2, Claudio Passino1,2.   

Abstract

Background The Seattle heart failure model or the cardiac and comorbid conditions (3C-HF) scores may help define patient risk in heart failure. Direct comparisons between them or versus N-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP) have never been performed. Methods Data from consecutive patients with stable systolic heart failure and 3C-HF data were examined. A subgroup of patients had the Seattle heart failure model data available. The endpoints were one year all-cause or cardiovascular death. Results The population included 2023 patients, aged 68 ± 12 years, 75% were men. At the one year time-point, 198 deaths were recorded (10%), 124 of them (63%) from cardiovascular causes. While areas under the curve were not significantly different, NT-proBNP displayed better reclassification capability than the 3C-HF score for the prediction of one year all-cause and cardiovascular death. Adding NT-proBNP to the 3C-HF score resulted in a significant improvement in risk prediction. Among patients with Seattle heart failure model data available ( n = 798), the area under the curve values for all-cause and cardiovascular death were similar for the Seattle heart failure model score (0.790 and 0.820), NT-proBNP (0.783 and 0.803), and the 3C-HF score (0.770 and 0.800). The combination of the 3C-HF score and NT-proBNP displayed a similar prognostic performance to the Seattle heart failure model score for both endpoints. Adding NT-proBNP to the Seattle heart failure model score performed better than the Seattle heart failure model alone in terms of reclassification, but not discrimination. Conclusions Among systolic heart failure patients, NT-proBNP levels had better reclassification capability for all-cause and cardiovascular death than the 3C-HF score. The inclusion of NT-proBNP to the 3C-HF and Seattle heart failure model score resulted in significantly better risk stratification.

Entities:  

Keywords:  Chronic heart failure; clinical scores; natriuretic peptides; risk stratification

Mesh:

Substances:

Year:  2018        PMID: 29569494     DOI: 10.1177/2047487318766580

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  3 in total

1.  Association of liver stiffness and cardiovascular outcomes in patients with heart failure: A systematic review and meta-analysis.

Authors:  Muhammad Shahzeb Khan; Tariq Jamal Siddiqi; Safi U Khan; Sanjiv J Shah; Lisa B VanWagner; Sadiya S Khan
Journal:  Eur J Prev Cardiol       Date:  2018-10-30       Impact factor: 7.804

2.  The MECKI score initiative: Development and state of the art.

Authors:  Elisabetta Salvioni; Alice Bonomi; Federica Re; Massimo Mapelli; Irene Mattavelli; Giuseppe Vitale; Filippo M Sarullo; Pietro Palermo; Fabrizio Veglia; Piergiuseppe Agostoni
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

Review 3.  Risk stratification in cardiomyopathy.

Authors:  Gianfranco Sinagra; Cosimo Carriere; Francesco Clemenza; Chiara Minà; Francesco Bandera; Denise Zaffalon; Paola Gugliandolo; Marco Merlo; Marco Guazzi; Piergiuseppe Agostoni
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.